Highlights in CINV from the 2016 MASCC/ISOO annual meeting.

[1]  R. Clark-Snow,et al.  Rolapitant for the prevention of nausea in patients receiving moderately or highly emetogenic chemotherapy. , 2016, Journal of Clinical Oncology.

[2]  R. Navari,et al.  Rolapitant for control of chemotherapy-induced nausea and vomiting (CINV) in patients with gynecologic cancer. , 2016, Journal of Clinical Oncology.

[3]  R. Navari,et al.  Rolapitant for prevention of chemotherapy-induced nausea and vomiting (CINV) in patients with breast cancer. , 2016 .

[4]  N. Masumori,et al.  Palonosetron with aprepitant plus dexamethasone to prevent chemotherapy‐induced nausea and vomiting during gemcitabine/cisplatin in urothelial cancer patients , 2015, International journal of urology : official journal of the Japanese Urological Association.

[5]  C. Gridelli,et al.  Safety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of cisplatin-based highly emetogenic chemotherapy in patients with cancer: two randomised, active-controlled, double-blind, phase 3 trials. , 2015, The Lancet. Oncology.

[6]  C. Gridelli,et al.  Safety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of moderately emetogenic chemotherapy or anthracycline and cyclophosphamide regimens in patients with cancer: a randomised, active-controlled, double-blind, phase 3 trial. , 2015, The Lancet. Oncology.

[7]  G. Rossi,et al.  Effect of netupitant, a highly selective NK1 receptor antagonist, on the pharmacokinetics of midazolam, erythromycin, and dexamethasone , 2013, Supportive Care in Cancer.